ProMIS Clears Alzheimer’s Trial Milestone, Solowin Closes $350M Deal, Solidion Grabs Spotlight with R&D Award

September 3, 2025

Breakthroughs, Buyouts, and Big Bets on the Future of Finance and Biotech Fuel Morning Momentum

DENVER, Colo., Sep 03, 2025 (247marketnews.com)- Wall Street opened today’s trading with investors zeroing in on a flurry of announcements from biotech innovators and fintech disruptors.

ProMIS Neurosciences (NASDAQ:PMN) surged in early action after announcing it received clearance from the independent Data and Safety Monitoring Board (DSMB) to move into the final dose escalation cohort in its Phase 1b Alzheimer’s trial of PMN310. With no observed ARIA cases and full enrollment of the second cohort completed, dosing at 20 mg/kg is now underway.

The news keeps the trial on track for interim data in Q2 2026 and top-line results by Q4 2026. CEO Neil Warma called the DSMB’s nod “validation” of PMN310’s targeted design, which avoids amyloid plaques and instead focuses on toxic oligomers believed to drive disease progression. The FDA recently granted Fast Track designation to PMN310, signaling continued momentum.

LIXTE Biotechnology (NASDAQ:LIXT) is shaking up its executive suite while relocating to Boca Raton, Florida, as part of a corporate restructuring aimed at cost-efficiency and future growth. The company added Lourdes Felix and Guy Primus to its board and named Peter Stazzone as its new CFO, with the collective CVs including leadership roles at Starbucks (NASDAQ:SBUX) and Microsoft (NASDAQ:MSFT).

CEO Geordan Pursglove, who took over in June, says the reshuffle brings “fresh perspective” to the company’s mission of advancing LB-100, its novel anti-cancer compound. With deeper management expertise and a more business-friendly HQ, LIXTE is positioning itself to accelerate development and strategic partnerships.

Solowin Holdings (NASDAQ:SWIN) is making headlines this morning after officially closing its $350 million acquisition of stablecoin tech firm AlloyX. The structure includes a 12-month lock-up for all selling shareholders and performance-based milestones tied to future valuations of $600 million and $1 billion.

Chairman and CEO Peter Lok said the deal is central to Solowin’s mission to build a compliant stablecoin-powered financial ecosystem, particularly targeting high-growth regions like the UAE, ASEAN, and Africa. The company is also in advanced talks to acquire a U.S.-licensed bank, a move Lok described as a “foundational pillar” for the firm’s future in regulated global finance.

Solidion Technology (NASDAQ:STI) is today’s most active pre-market listing, following news that its E-GRIMS graphite production technology, developed with Oak Ridge National Laboratory, won a 2025 R&D 100 Award, a prestigious honor in global innovation.

The breakthrough method enables low-energy, scalable, and eco-friendly graphite production, a crucial component for lithium-ion batteries. CEO Jaymes Winters praised the collaboration with ORNL, calling it a major step toward “sustainable energy solutions.” Solidion is now advancing to pilot and commercial-scale deployment, and investors are responding.

Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PMN, LIXT, SBUX, MSFT, SWIN, STI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.